Clinical Trials Logo

Cardiovascular Disease clinical trials

View clinical trials related to Cardiovascular Disease.

Filter by:

NCT ID: NCT06263452 Not yet recruiting - Clinical trials for Cardiovascular Disease

Beta-Blocker Influences on Inflammatory and Neural Responses to Stress

Start date: March 2024
Phase: Phase 4
Study type: Interventional

The purpose of this study is to map the neural and molecular mechanisms underlying psychological stress-induced changes in inflammation which could reveal new targets for intervention to reduce the risk of cardiovascular disease.

NCT ID: NCT06235658 Recruiting - Clinical trials for Cardiovascular Diseases in Old Age

Yoga in Older Cardiac Patients

Start date: November 15, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare, at 3 months, the effects of a yoga intervention on physical health, including balance, muscle strength, physical activity levels, cardiac autonomic function, and physical vulnerability, as well as psychological health, including depressive symptoms and anxiety, in cardiac patients who are older than 65 years old and randomized to the intervention or control group. The main questions aim to 1) determine if yoga can improve physical health outcomes such as balance, muscle strength, cardiac function, and physical vulnerability in older adults with cardiovascular disease, and 2) determine if yoga can positively impact psychological health, including reducing depressive symptoms and anxiety in this population. Participants in the intervention group will attend yoga sessions twice a week for three months. The intervention group will be asked to complete surveys and physical function assessments at the beginning and three months later. Researchers will compare the intervention group and the control group to see if there is any difference and improvement in physical and psychological health between the two groups.

NCT ID: NCT06225544 Not yet recruiting - Clinical trials for Cardiovascular Disease

Lumasiran in Hyperoxalaemic Patients on Haemodialysis

LHOxH
Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

This study will look at how well a drug that reduced the amount of oxalate in the body works in patients that have kidney disease and need dialysis treatment. People with kidney disease often have higher levels of oxalate in the blood. People with kidney disease are also at higher risk of having heart attacks, heart disease and strokes (these are called cardiovascular diseases). It is thought that high oxalate levels may increase the risk of these diseases. So we would like to study if this medicine can lower the amount of oxalate in the blood of dialysis patients and see if there is any change in the health of their heart. This medicine is already used for people who have high oxalate levels because of a genetic cause and has been used safely for patients on dialysis. The study will put the participants randomly into either the group getting the study medicine or the group getting a placebo (this will be a solution of saline water). Neither participants not the doctors will know whether the drug or placebo is given until after the end of the study. At the start of the study we will ask all the participants to have an echocardiogram (an ultrasound of the heart) and again 6 months later at the end of the study. We will also take blood tests once a month when the participants come for dialysis.

NCT ID: NCT06142838 Recruiting - Clinical trials for Cardiovascular Diseases

Community Pharmacist Intervention to Enhance Adherence in Cardiovascular Drug Initiators

PHARM-ADHERE
Start date: October 3, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate a community pharmacist intervention aimed at improving medication adherence in patients starting newly prescribed medication for cardiovascular disease prevention. The main questions it aims to answer are: - Does this community pharmacist intervention improve medication adherence? - Which patients benefit the most from the intervention? - How do patients experience the start-up of newly prescribed medication (which questions do they have and do they experience side effects?)? - How do patients and pharmacists experience the intervention?

NCT ID: NCT06014515 Recruiting - Clinical trials for Cardiovascular Disease

Single-tracer Multiparametric PET Imaging

Start date: February 14, 2024
Phase: Early Phase 1
Study type: Interventional

The overarching goal of this project is to develop and evaluate a single-tracer multiparametric positron emission tomography (PET) imaging solution for simultaneous imaging of blood flow and glucose metabolism using 18F-fluorodeoxyglucose (FDG) alone. The investigators working hypothesis is that quantitative blood flow can be extracted from dynamic 18F-FDG PET data by use of tracer kinetic modeling, in addition to glucose metabolism that 18F-FDG is conventionally used for.

NCT ID: NCT06004544 Recruiting - Clinical trials for Cardiovascular Diseases in Pregnancy

Prospective Pakistan Registry of Echocardiographic Screening in Asymptomatic Pregnant Women

PRESAP
Start date: February 6, 2023
Phase:
Study type: Observational [Patient Registry]

Consecutive obstetric patients attending routine antenatal visits were enrolled in this ongoing registry. A standardized 2D transthoracic echocardiogram (TTE) protocol was employed. Ejection fraction (EF) was quantified using biplane Simpson's method.

NCT ID: NCT05972850 Enrolling by invitation - Clinical trials for Cardiovascular Disease

Vivo Heart: Home-Based Virtual Exercise Program for Older Adults With Cardiovascular Disease

Start date: February 2024
Phase: N/A
Study type: Interventional

This pilot study will assess the feasibility and generate preliminary efficacy data of a novel, synchronous, home-based exercise training program for rural older adults with cardiovascular disease (CVD) using Vivo, an online, live, small group fitness program developed for older adults. It uses individually tailored dual-tasked (i.e., cognitive-motor) exercises to improve strength, endurance, balance, and cognition and incorporates social engagement. Certified trainers deliver instruction and coaching through an interactive session (45 min, 2-3 times/week) delivered over 12 weeks. Vivo Heart adapts this unique program to meet the cardiac rehabilitation needs of older adults with CVD. The specific aims are to evaluate the feasibility, acceptability, and uptake of Vivo Heart (Aim 1) and obtain pre- and post-intervention measures of exercise capacity, strength, lower-extremity physical function, cognition, quality of life, stress, fatigability, physical activity, and aging biomarkers (Aim 2).

NCT ID: NCT05967000 Active, not recruiting - Clinical trials for Cardiovascular Disease

Evaluating a Preventive Heart Health Programme for Women at Midlife

Phenomenon
Start date: June 1, 2023
Phase:
Study type: Observational

This study examines the factors that limit or support the implementation of a pilot heart health program for perimenopausal women. The investigators evaluate the effectiveness of this program in raising awareness and promoting behavior change to maintain cardiovascular health.

NCT ID: NCT05904639 Not yet recruiting - Clinical trials for Cardiovascular Disease

Decoding Your Diet (DYD)

DYD
Start date: July 2023
Phase: Early Phase 1
Study type: Interventional

Our study will determine if a high quality AHA plant-based diet intervention can promote a genetic signature that is protective against CVD. Our development of GE mutational signatures in Blacks/African Americans with a high CVD burden can inform of changes patients can implement in their diet and lifestyle to decrease the CVD risk burden.

NCT ID: NCT05888506 Completed - Clinical trials for Cardiovascular Diseases

Ketone Ester Supplementation and Nocturnal Blood Pressure

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

Cardiovascular disease (CVD) is the number one cause of death globally and high blood pressure (i.e., hypertension) is the leading modifiable risk factor for CVD and all-cause mortality. Advancing age is the primary risk factor for hypertension and CVD. Moreover, compared to younger adults, older adults exhibit reduced nocturnal dipping of blood pressure resulting in elevated nighttime blood pressure values, which are a better predictor of cardiovascular outcomes than daytime blood pressure. Intriguingly, recently published rodent data suggests that ketone supplementation protects against hypertension, blood vessel dysfunction, and kidney injury. Whether ketone supplementation provides vascular health benefits in humans remains to be determined. Therefore, the investigations seek to conduct an acute ketone supplementation study to determine whether ketone supplementation may restore a more healthy nighttime blood pressure phenotype in middle-aged and older adults. The investigations will also determine whether ketone supplementation influences nocturnal heart rate variability, a non-invasive of autonomic function that may be influenced by ketone supplementation in a manner that influences blood pressure.